
Sign up to save your podcasts
Or
Dr. Peter Quiros joins host Dr. Amanda Redfern to discuss the recent JAMA Ophthalmology article "The Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," the first study to report a possible association between semaglutide (Wegovy, Ozempic, Novo Nordisk) and nonarteritic anterior ischemic optic neuropathy (NAION). Dr. Quiros provides an overview of what the study showed and what remains unknown, and how ophthalmologists should discuss these recent findings with their patients.
Check out the Semaglutide and NAION patient brochure, courtesy of the North American Neuro-Ophthalmology Society (NANOS), and available from www.nanosweb.org.
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.
4.9
4747 ratings
Dr. Peter Quiros joins host Dr. Amanda Redfern to discuss the recent JAMA Ophthalmology article "The Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," the first study to report a possible association between semaglutide (Wegovy, Ozempic, Novo Nordisk) and nonarteritic anterior ischemic optic neuropathy (NAION). Dr. Quiros provides an overview of what the study showed and what remains unknown, and how ophthalmologists should discuss these recent findings with their patients.
Check out the Semaglutide and NAION patient brochure, courtesy of the North American Neuro-Ophthalmology Society (NANOS), and available from www.nanosweb.org.
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.
41 Listeners
97 Listeners
16 Listeners
5 Listeners
11 Listeners
271 Listeners
9 Listeners
12 Listeners
20 Listeners
8 Listeners
10 Listeners
17 Listeners
16 Listeners
16 Listeners
0 Listeners